RNA
Atrium Therapeutics, Inc.Company Information
- Company Name
- Atrium Therapeutics, Inc.
- CIK
- CIK0002093101
- Category
- Non-accelerated filer<br>Smaller reporting company<br>Emerging growth company
- Ticker: Exchange
- RNA: Nasdaq
- Fiscal Year End
- December 31
- Owner Organization
- 03 Life Sciences
- SIC
- 2834
- SIC Description
- Pharmaceutical Preparations
- Ticker
- RNA
SEC filing data through
Insider Sentiment
- Last purchase
- —
- Last sale
- —
- Shares purchased (TTM)
- 0
- Shares sold (TTM)
- 0
Institutional Sentiment
- As of
- 2026-06-30
- Institutional shares owned
- 12,684,532
- Shares outstanding
- 17,106,000
- Ownership
- 74.15%
Earnings Market Reaction
- Filing date
- 2026-08-13
- Price on filing date
- —
- 1-month reaction
- 15.09%
- 3-month reaction
- …
Balance Sheet
Values in millions ($)| Line item | 2026-06-30 | 2026-03-31 | Subscriber-only column | Subscriber-only column | Subscriber-only column | Subscriber-only column | Subscriber-only column | Trend |
|---|---|---|---|---|---|---|---|---|
Assets Current | ||||||||
| Cash And Cash Equivalents At Carrying Value | 72 | 268 | ||||||
| Short Term Investments | 192 | - | ||||||
| Prepaid Expense Current | 5 | 3 | ||||||
| Restricted Cash Current | 0 | - | ||||||
| Other Assets Current | 6 | 0 | ||||||
| Assets Current | 275 | 286 | ||||||
| Restricted Cash Noncurrent | 0 | 0 | ||||||
| Property Plant And Equipment Net | 4 | 4 | ||||||
| Operating Lease Right Of Use Asset | 1 | 2 | ||||||
| Assets | 281 | 292 | ||||||
Liabilities Current | ||||||||
| Accounts Payable Current | 4 | 1 | ||||||
| Accrued Liabilities Current | 13 | 7 | ||||||
| Operating Lease Liability Current | 2 | 3 | ||||||
| Contract With Customer Liability Current | 9 | 9 | ||||||
| Liabilities Current | 32 | 22 | ||||||
| Contract With Customer Liability Noncurrent | 34 | 36 | ||||||
| Other Liabilities Noncurrent | 1 | 0 | ||||||
| Liabilities | 66 | 58 | ||||||
Stockholders Equity | ||||||||
| Common Stock Value | 0 | 0 | ||||||
| Additional Paid In Capital | 223 | 222 | ||||||
| Retained Earnings Accumulated Deficit | -8 | 12 | ||||||
| Accumulated Other Comprehensive Income Loss Net Of Tax | -0 | - | ||||||
| Stockholders Equity | 215 | 234 | ||||||
| Liabilities And Stockholders Equity | 281 | 292 | ||||||
| Common Stock Par Or Stated Value Per Share | 0.00 | 0.00 | ||||||
| Common Stock Shares Authorized | 400 | 400 | ||||||
| Common Stock Shares Issued | 17 | 17 | ||||||
| Shares Outstanding | 17 | 17 | ||||||
| Preferred Stock Par Or Stated Value Per Share | 0.00 | 0.00 | ||||||
| Preferred Stock Shares Authorized | 40 | 40 | ||||||
| Preferred Stock Shares Issued | 0 | 0 | ||||||
| Preferred Stock Shares Outstanding | 0 | 0 | ||||||
Select a line item above to chart it.
Recent filings
Financial statements beyond 3 years are for subscribers only.
Unlock 17+ years of income statements, balance sheets, and cash flow statements
Start 7-day free trialAtrium Therapeutics, Inc. (RNA) — SEC Financial Statements & Analysis
Atrium Therapeutics, Inc. (RNA) is a pharmaceutical preparations company, incorporated in DE. Atrium Therapeutics, Inc. trades on Nasdaq as: RNA. Atrium Therapeutics, Inc. (RNA)'s most recent SEC filing is a Form 10-Q for the period ended 2026-06-30, filed with the SEC on 2026-08-13. Based on that filing, Atrium Therapeutics, Inc. carries a market cap of $230.08M, a P/B ratio of 1.07x, and an enterprise value of $157.32M. On the balance sheet, it maintains a current ratio of 8.73x, a quick ratio of 8.59x, working capital of $243.54M, a debt-to-equity ratio of 0.31x, a debt ratio of 0.24, and net debt of $-72.75M. Figures sourced from SEC EDGAR.
- Market Cap
- $230.08M
- P/B TTM
- 1.07x
- Debt To Equity
- 0.31x
Data as of 2026-06-30 · Source: SEC EDGAR
Frequently Asked Questions
What industry is Atrium Therapeutics, Inc. in?
Atrium Therapeutics, Inc. (RNA) operates in the Pharmaceutical Preparations industry.
What exchange does RNA trade on?
Atrium Therapeutics, Inc. (RNA) trades on the Nasdaq.
Where is Atrium Therapeutics, Inc. incorporated?
Atrium Therapeutics, Inc. is incorporated in DE.
When was Atrium Therapeutics, Inc. (RNA)'s most recent SEC filing?
Atrium Therapeutics, Inc. (RNA)'s most recent SEC filing is a Form 10-Q for the period ended 2026-06-30, filed with the SEC on 2026-08-13.
What is RNA's market cap?
Atrium Therapeutics, Inc. (RNA) has a market capitalization of $230.08M as of 2026-06-30.